According to Zhen, the trial comparing nivolumab (Opdivo) plus chemotherapy vs chemotherapy alone led to an overall survival (OS) benefit in patients with a PD-L1 combined positive score (CPS) of 5 or ...
The biologics license application for RP1 (vusolimogene oderparepvec) plus nivolumab in advanced melanoma was accepted by the FDA with priority review. The FDA accepted the biologics license ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback